Drug intelligence / Profile preview

palivizumab

Development stage: Approved
Lead developer: MedImmune
Modality: Monoclonal Antibodies → Antibody-Based Therapeutics
Administration: Intramuscular

Overview

Palivizumab is a humanized monoclonal antibody produced by recombinant DNA technology, used to prevent serious lower respiratory tract disease caused by respiratory syncytial virus (RSV) infection in pediatric patients at high risk, such as premature infants or those with certain heart or lung conditions. It works by binding to the fusion (F) protein of RSV, thereby inhibiting viral entry into host cells and preventing infection. Palivizumab provides passive immunity and exhibits both neutralizing and fusion-inhibitory activity against RSV. It is administered via intramuscular injection, typically once monthly during the RSV season[1][2][3][6][7].

Brand names: Synagis
Other names: Synagis biosimilar

Targets

RSV F (Respiratory syncytial virus fusion protein)

Beyond the preview

Go deeper on palivizumab.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on palivizumab.

Explore the full profile